Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the European Union Drugs Agency (EUDA).
Notes:
Data for England and Wales are not national level
¹ - Data are laboratory reports and not notifications
A = acute cases
AC = acute and chronic cases
C = chronic cases
Reitox national focal points. For primary sources, study details and data before 2003, see Table INF-14.
See also 'General notes for interpreting data' on the Explanatory notes and help page.
Sources:
Reitox national focal points.